
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Stryker Corporation (SYK)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SYK (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $432.27
1 Year Target Price $432.27
13 | Strong Buy |
9 | Buy |
9 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.08% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 148.97B USD | Price to earnings Ratio 51.54 | 1Y Target Price 432.27 |
Price to earnings Ratio 51.54 | 1Y Target Price 432.27 | ||
Volume (30-day avg) 32 | Beta 0.91 | 52 Weeks Range 328.46 - 404.87 | Updated Date 08/29/2025 |
52 Weeks Range 328.46 - 404.87 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.84% | Basic EPS (TTM) 7.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When After Market | Estimate 3.07 | Actual 3.13 |
Profitability
Profit Margin 12.25% | Operating Margin (TTM) 21.95% |
Management Effectiveness
Return on Assets (TTM) 7.74% | Return on Equity (TTM) 14.25% |
Valuation
Trailing PE 51.54 | Forward PE 29.33 | Enterprise Value 163089684811 | Price to Sales(TTM) 6.25 |
Enterprise Value 163089684811 | Price to Sales(TTM) 6.25 | ||
Enterprise Value to Revenue 6.9 | Enterprise Value to EBITDA 28.53 | Shares Outstanding 382307008 | Shares Floating 344604152 |
Shares Outstanding 382307008 | Shares Floating 344604152 | ||
Percent Insiders 5.36 | Percent Institutions 81.66 |
Upturn AI SWOT
Stryker Corporation

Company Overview
History and Background
Stryker Corporation was founded in 1941 by Dr. Homer Stryker, an orthopedic surgeon. Initially focused on developing medical equipment to improve patient outcomes, Stryker has grown through innovation and acquisitions into a leading global medical technology company.
Core Business Areas
- MedSurg and Neurotechnology: Offers products and equipment for surgical procedures, endoscopy, communications, and neurotechnology, including neurosurgical, neurovascular, and spinal devices.
- Orthopaedics and Spine: Focuses on implants used in joint replacement, trauma, sports medicine, and spinal surgeries.
Leadership and Structure
Kevin A. Lobo serves as the Chairman and CEO. The company operates with a divisional structure aligned with its core business segments, with each segment having its own leadership team reporting to corporate executives.
Top Products and Market Share
Key Offerings
- Joint Replacement Implants: Implants for hip, knee, and shoulder replacements. Stryker is a major player in this market, competing with Zimmer Biomet (ZBH), Johnson & Johnson (JNJ), and Smith & Nephew (SNN). Market share data varies by region, but Stryker is consistently among the top three globally.
- Surgical Navigation Systems: These systems provide real-time surgical guidance, improving accuracy and efficiency. Competitors include Medtronic (MDT) and Brainlab. Stryker's Q Guidance System has been driving growth in this segment.
- Endoscopy Equipment: Visualization systems and related equipment used in minimally invasive surgery. Olympus and Karl Storz are key competitors in this market.
Market Dynamics
Industry Overview
The medical technology industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in surgical procedures and diagnostic tools.
Positioning
Stryker is positioned as a leader in the medical technology industry, known for its innovation, broad product portfolio, and strong brand reputation. Its competitive advantages include a robust R&D pipeline, a global sales network, and a history of successful acquisitions.
Total Addressable Market (TAM)
The global medical devices market is estimated at approximately $500 billion USD. Stryker is well-positioned to capture a significant portion of this market through its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diverse product portfolio
- Extensive global sales network
- Robust R&D pipeline
- History of successful acquisitions
Weaknesses
- High product development costs
- Exposure to healthcare regulatory changes
- Dependence on third-party suppliers
- Price pressure from competitors
Opportunities
- Expanding into emerging markets
- Developing new minimally invasive surgical technologies
- Leveraging data analytics and AI for personalized medicine
- Acquiring complementary businesses
Threats
- Increased competition from existing players and new entrants
- Changes in healthcare reimbursement policies
- Product liability claims
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- ZBH
- JNJ
- MDT
- BSX
Competitive Landscape
Stryker's advantages include its broad product portfolio, strong brand reputation, and extensive global sales network. Disadvantages may include high product development costs and exposure to healthcare regulatory changes.
Major Acquisitions
Vocera Communications
- Year: 2022
- Acquisition Price (USD millions): 3090
- Strategic Rationale: To expand Stryker's digital capabilities and presence in the healthcare communication space.
Growth Trajectory and Initiatives
Historical Growth: Stryker has demonstrated consistent revenue and earnings growth over the past decade, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued growth for Stryker, driven by its innovative product pipeline and expansion into new markets. Revenue growth is expected to be in the mid-single digits.
Recent Initiatives: Recent initiatives include investments in robotic surgery, digital health solutions, and expansion into emerging markets.
Summary
Stryker is a strong medical technology company with a diverse product portfolio and a history of consistent growth. Its innovative products and strategic acquisitions drive expansion, particularly in robotic surgery and digital health. Challenges include navigating healthcare regulations and managing high product development costs but the company has strong strengths that are able to combat them. Strong and consistent cash flow support investments and dividend payouts and provide security for all shareholders.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Relations, Market Research Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stryker Corporation
Exchange NYSE | Headquaters Portage, MI, United States | ||
IPO Launch date 1988-02-01 | Chairman, CEO & President Mr. Kevin A. Lobo | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.stryker.com |
Full time employees 53000 | Website https://www.stryker.com |
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.